contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


c-rad-celebrates-success-in-the-uk-sgrt-tender-won-at-northern-centers-for-cancer-care

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

C-Rad operates in the medical technology industry and focuses on the development and manufacture of systems for radiation therapy of cancer. The company's products are aimed at healthcare institutions and oncologists. The business is present on a global level, with a main presence in Europe, North America and Asia. C-Rad was founded in 2004 and is headquartered in Uppsala, Sweden.

C-Rad

C-RAD has been announced as the vendor of choice and will supply cutting-edge SGRT (Surface Guided Radiation Therapy) solution to Northern Centers for Cancer Care in the UK. The agreement includes...

<div class="mfn-preamble"><p><strong>C-RAD has been announced as the vendor of choice and will supply cutting-edge SGRT (Surface Guided Radiation Therapy) solution to Northern Centers for Cancer Care in the UK. The agreement includes multiple Catalyst+ HD systems split across two sites: Freeman Hospital in Newcastle and Cumberland Infirmary in Carlisle.</strong></p></div><div class="mfn-body"><p>Northern Center for Cancer Care provide radiation oncology services to diagnose, treat and support people with cancer. The two centers in North England play a critical role in the cancer service across NHS north-east and west and will become strategic and important SGRT reference centers for C-RAD in the future. These two new sites join James Cook Hospital in Middlesbrough in offering to cancer patients in North England the latest C-RAD SGRT technology during their cancer treatment pathway.</p><p>Catalyst+ HD systems will be delivered with the complete software suite including modules for Respiratory Gating, Patient Setup &amp; Positioning as well as Motion Monitoring. C-RAD SGRT technology provides the customer with a tool for accurate patient setup prior to the treatment and continuous monitoring of the patient during a treatment fraction. The technology enables accuracy and safety for the patient to support high precision treatment techniques -such as DIBH (Deep Inspiration Breath Hold)- as well as efficiency in a complex treatment workflow.</p><p>“We are thrilled to again be selected by this NHS trust and to be part of the important cancer care in the UK with our latest Surface Guided Radiation Therapy technology”, said Cecilia de Leeuw, CEO and President of C-RAD AB. “The UK is an important market for C-RAD and I am enthusiastic to see our customers choosing our technology, to help cancer patients receive the safest, most effective and accurate treatment possible.”</p><p>The total order has a value of approx. 7.8 MSEK which also includes a service contract for several years. Delivery and installation are expected to commence late 2023.</p></div><div class="mfn-footer mfn-contacts mfn-e520b92ae86a"><p><strong class="mfn-heading-1">For further information:</strong></p><hr><p>Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, <a rel="noopener" href="mailto:investors@c-rad.com">investors@c-rad.com</a><br>Christoffer Herou, CFO, +46 (0)725 82 86 16, <a rel="noopener" href="mailto:investors@c-rad.com">investors@c-rad.com</a></p></div><div class="mfn-footer mfn-about mfn-1fc3b360975a"><p><strong class="mfn-heading-1">About C-RAD</strong></p><hr><p>C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.</p><p>C-RAD. Inspiring excellence in cancer treatment.</p><p>C-RAD AB is listed on NASDAQ Stockholm.</p><p>For more information on C-RAD, please visit&nbsp;<a rel="noopener" href="http://www.c-rad.com/">http://www.c-rad.com</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/f11b0abf-d096-40be-9596-6bf21144f796/c-rad-celebrates-success-in-the-uk-sgrt-tender-won-at-northern-centers-for-cancer-care.pdf" class="mfn-generated mfn-primary">C-RAD celebrates success in the UK - SGRT tender won at Northern Centers for Cancer Care</a></p></div>

C-RAD celebrates success in the UK - SGRT tender won at Northern Centers for Cancer Care